Bali Muralidhar

Bali is Managing Partner and Chief Investment Officer at Abingworth, a leading transatlantic life sciences investment firm. He has over 15 years professional experience in healthcare across a range of functions including venture investing, CCD, R&D, clinical practice, and teaching. He represents Abingworth on the boards of Anjarium, Glycomine, NuCana (NCNA), Reneo Pharmaceuticals (RPHM), Spruce Biosciences (SPRB) and Wugen. He is also an executive officer on the joint steering committee of CymaBay. Prior to Abingworth, Bali was a senior partner at MVM Partners LLP in London where he completed investments in and served on the boards of several companies, both public and private. In 2018, Bali was named among Financial News’ Rising Stars in Private Equity, which celebrated 25 men and women under the age of 40 standing out in the European private equity industry. Before MVM, Bali was a member of Bain Capital’s healthcare deal team. Bali obtained a degree in clinical medicine from the University of Oxford and practiced general surgery at the John Radcliffe and Addenbrooke’s Hospitals in Oxford and Cambridge, respectively. He has a PhD in translational cancer research from the MRC Cancer Cell Unit, University of Cambridge, and has published over a dozen peer reviewed papers. He was also a Bye-Fellow in Medical Sciences at Downing College, Cambridge where he taught pathology, surgery, and medicine.